AVEO Pharmaceuticals, Inc. (AVEO), InterMune Inc (ITMN), and Galena Biopharma Inc (GALE): 2 Biotechs To Avoid, 1 To Buy

The earnings season is in full swing and investors are flooded with fundamental information to reassess their investments. While fundamental information should be a basic component for any investment decision, it becomes irrelevant in the biotechnology industry. The companies in this sector are usually involved in development of candidates without much topline or bottom line information. The trades by institutions and insiders are a more effective way for potential investors to assess the upcoming catalysts and price trends for biotech stocks.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is a cancer therapeutics company and is involved in the discovery, development, and commercialization of various oncology treatments. The primary product of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is tivozanib, which the company is pushing for the treatment of advances in renal cell carcinoma. As opposed to most small biotechnology companies, it has a pretty rich pipeline with a number of promising candidates. The leading candidates include TAURUS, Ficlatuzumab, and the exploratory study for tivozanib, BATON-RCC.

Despite a solid pipeline, the company has seen some heaving selling from institutions and light buying by insiders. In the last six months, institutional ownership has come down by a staggering 35%, which is the primary reason behind the major price slump. During the same period, insiders have increased their ownership by 6.4%. Despite major sales by institutions, only a single sell-side analyst has a “sell” rating on the stock, with others evenly distributed between “hold” and “buy.” At current levels, it is better that investor’s stay away from the company until more long term catalysts emerge.

InterMune Inc (NASDAQ:ITMN)

InterMune Inc (NASDAQ:ITMN) is involved in the discovery, development, and commercialization of drugs for the treatment of orphan fibrotic diseases and pulmonology. The leading drug of InterMune Inc (NASDAQ:ITMN) is Pirfenidone, which is an orally active drug for IPF.

In the last two years, the company has lost almost 80% of its value. The institutional investors are increasingly losing faith in the stock and have dumped almost 18 million shares in the last six months, reducing their ownership by 39%. Despite these issues, the sell-side still has stellar rating on the stock, with a target price of $14, 35% upside to current price levels. Investors should still avoid the stock because institutional selling has really beaten down the price and there are no major catalysts approaching that can force a rally.

Galena Biopharma Inc (NASDAQ:GALE)

Galena Biopharma Inc (NASDAQ:GALE) is a biotechnology company involved in the development of oncology treatments. The current valuations of Galena Biopharma Inc (NASDAQ:GALE) are tied to its leading product candidate, NeuVax. NeuVax is currently in Phase III clinical trials for the prevention of breast cancer recurrence. The company’s Folate Binding Protein-E39 is in Phase 1/2 trials for preventing the recurrence of endometrial adenocarconimas and ovarian cancers.

Galena Biopharma Inc (NASDAQ:GALE) is currently operating in a healthcare sector, which is facing some serious candidate shortage. This has increased the demand for small biopharmaceutical companies with promising drug candidates. In the last six months, the interest of institutional investors has significantly increased in Galena Biopharma Inc (NASDAQ:GALE) due to its acquisition prospects and cheap valuations.

Institutions have increased their holdings in Galena Biopharma Inc (NASDAQ:GALE) by 18% and have added almost 1.5 million shares. The sell-side also has a pretty favorable view of the company and is currently giving a unanimous “buy” rating for the stock. The mean target price is currently $4.90, which is an approximately 100% upside to current price levels.

Conclusion

Investors should avoid AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) and InterMune Inc (NASDAQ:ITMN) for the time being because these companies are witnessing some heaving dumping by institutions, which will continue to beat down the price. Galena remains a top pick in the biotechnology industry due to its cheap valuations and high probability of an acquisition by major players like TEVA and AstraZeneca.

The article 2 Biotechs To Avoid, 1 To Buy originally appeared on Fool.com and is written by Mohsin Saeed.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!